CClinicalTrials.gg
Enrolling by invitationNCT07754357ICBN/ESPUpdated Aug 10, 2026

Ultrasound-Guided T2 Erector Spinae Plane Block Versus Intercostobrachial Block in AV Fistula Surgery.

An interventional study of Ultrasound Guided Intercostobrachial Nerve Block and Ultrasound Guided Erector Spinae Plane Block at T2 level in ESRD (End Stage Renal Disease), sponsored by Fatma Hatem Mokhtar. Enrolling by invitation at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Fatma Hatem Mokhtar · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to determine whether ultrasound guided ESP block at 2nd thoracic vertebrae is non inferior to ultrasound guided ICBN block as adjunct to supraclavicular brachial plexus block in achieving complete sensory blockade of the medial upper arm during AVF superficialization

Read the detailed description

Arteriovenous fistula (AVF) superficialization is an essential procedure for patients with end-stage renal disease . The supraclavicular brachial plexus block is commonly used for upper extremity surgeries .Because the ICBN originates from the T2 nerve root below the C5-T1 nerve roots comprising the brachial plexus, brachial plexus blocks are ideally supplemented with an ICBN infiltration block for medial upper arm coverage.The ICBB requires precise ultrasound guidance to target the ICBN, which is small and variably located, making it technically challenging and time-intensive.

ESP block at T2 level can provide broad coverage, ease of Performance, superficial injection and requiring less technical expertise compared to the ICBB .

The patients are randomly allocated into 2 groups :

  1. Erector spinae plane block group (Group ESP): will receive 10 ml of 0.5% bupivacaine injected into the erector spinae plane at T2 level under ultrasound guidance.
  2. Intercostobrachial block group (Group ICBB): will receive 10 ml of 0.5% bupivacaine injected around intercostobrachial nerve under ultrasound guidance. • Standard Supraclavicular Brachial plexus Block will be performed for all patients using 20 ml of 0.5% bupivacaine under ultrasound guidance.
02

Conditions studied

  • ESRD (End Stage Renal Disease)

Keywords

  • AVF superficialization
  • Intercostobrachial block
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

    • Adults scheduled for upper extremity surgeries under regional anesthesia.

      • Age: 18-65 years.
      • American society of Anesthesiologists (ASA) III.
      • Body Mass Index (BMI) \< 35 kg/m².

Exclusion criteria

Exclusion Criteria:

  • •Allergy to local anesthetics.

    • Coagulopathy or infection at injection sites.
    • Pre-existing neuropathy or significant psychiatric disorders.
    • Pregnant or lactating women.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    Ultrasound Guided Intercostobrachial Nerve Block

    1. Position: patient supine with arm abducted. 2. Ultrasound setup: High frequency probe positioned at upper axillary region. 3. Technique: Needle will be advanced into subcutaneous tissue, in-plane to target intercostobrachial nerve near axillary artery. 4. Drug: 10 ml of 0.5% bupivacaine.

    Procedure: Ultrasound Guided Intercostobrachial Nerve Block

  • Active comparator
    Ultrasound Guided Erector Spinae Plane Block at T2 level

    1. Position: patient sitting or in lateral decubitus. 2. Ultrasound setup: High frequency linear transducer will be placed in a parasagittal 2-3 cm lateral to spinous process at T2 level, erector spinae muscles will be identified superficial to the tip of T2 transverse process, patient's skin anesthetized with 3 ml of 2 % lidocaine subcutaneously, the tip of the 22- gauge 80-mm block needle (Sonoplex, Pajunk Medical, Geisingen, Germany) needle will be placed into the facial plane on the deep (anterior) aspect of erector spinae muscle. location of needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process then 10 ml of 0.5% bupivacaine will be injected into the facial plane that will be confirmed by visible hydrodissection .

    Procedure: Ultrasound Guided Erector Spinae Plane Block at T2 level

Interventions

  • ProcedureUltrasound Guided Intercostobrachial Nerve Block

    1. Position: patient supine with arm abducted. 2. Ultrasound setup: High frequency probe positioned at upper axillary region. 3. Technique: Needle will be advanced into subcutaneous tissue, in-plane to target intercostobrachial nerve near axillary artery. 4. Drug: 10 ml of 0.5% bupivacaine.

    Also known as: ICBB

  • ProcedureUltrasound Guided Erector Spinae Plane Block at T2 level

    1. Position: patient sitting or in lateral decubitus. 2. Ultrasound setup: High frequency linear transducer will be placed in a parasagittal 2-3 cm lateral to spinous process at T2 level, erector spinae muscles will be identified superficial to the tip of T2 transverse process, patient's skin anesthetized with 3 ml of 2 % lidocaine subcutaneously, the tip of the 22- gauge 80-mm block needle(Sonoplex, Pajunk Medical, Geisingen, Germany) needle will be placed into the facial plane on the deep (anterior) aspect of erector spinae muscle. location of needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process then 10 ml of 0.5% bupivacaine will be injected into the facial plane that will be confirmed by visible hydrodissection .

05

What researchers measure

Primary outcomes

  1. Proportion of patients achieving complete sensory blockade during AVF superficialization

    No discomfort and no need for sedation or conversion to general anesthesia

    Time frame: baseline then at 15,30,60,120 minutes intraoperative assessment for vital signs and sensory blockade

Secondary outcomes

  1. Time to achieve complete sensory blockade.

    How much time required to achieve complete sensory blockade in minutes

    Time frame: Time for complete sensory blockade in minutes within 30 minutes

  2. Patient's satisfaction (assessed using Likert scale).

    Patient satisfaction was evaluated using a five-point Likert scale (1 = very dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, and 5 = very satisfied)

    Time frame: At the first 24 hours

  3. Total opioid consumption in 24 hours

    Total opioid consumption in 24 hours postoperative in mg /kg

    Time frame: in the first 24 hours

  4. The visual analog scale(VAS)

    measure a patient pain intensty ,commonly used interpretation is 0:no pain,1-3 :mild pain.4-6:moderate pain,7-10 :sever pain

    Time frame: in the first 12 hours

06

Study locations

1 site
  • Aswan university hospital
    Aswān, Egypt
07

References and documents

Related links

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT07754357
Lead sponsor
Fatma Hatem Mokhtar
Collaborators
Aswan University Hospital
Responsible party
Fatma Hatem Mokhtar (Resident doctor of anesthesia,ICU&pain management, Aswan University Hospital) — Sponsor-investigator
First posted
Aug 10, 2026
Start date
Jul 21, 2026 (estimated)
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Aug 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion